Summit Therapeutics CEO Applauds UK Antibiotics Market Pilot
But Summit’s Product Ridinilazole Is Not Taking Part This Time
The world hopes a UK pilot can offer guidance on making novel antibiotics commercially viable, Summit Therapeutics CEO tells Scrip, but adds his lead asset won’t take part this time.
You may also be interested in...
ConserV CEO tells Scrip why the late-stage vaccine developer has entered an mRNA development pact with eTheRNA of Belgium and about the UK biotech’s hopes for finding a universal jab against the entire coronavirus family.
Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.